377 Hyperthyroidism Flashcards
Smoking is a minor risk factor for the development of Graves disease but is a major risk factor for developing this clinical manifestation (H20 C377 P2703)
Ophthalmopathy
In the elderly, features of thyrotoxicosis may be subtle or masked, and patients may present mainly with fatigue and weight loss, a condition known as: (H20 C377 P2703)
Apathetic thyrotoxicosis
Most common symptoms [3] of Graves disease (H20 C377 P2703)
Hyperactivity, irritability, dysphoria
Most common sign of Graves disease (H20 C377 P2703)
Tachycardia
Thyrotoxicosis is sometimes associated with a form of hypokalemic periodic paralysis; this disorder is particularly common in: (H20 C377 P2704)
Asian males
The most common cardiovascular manifestation of Graves disease is: (H20 C377 P2704)
Sinus tachycardia
Atrial fibrillation in Graves disease is more common in patients age: (H20 C377 P2704)
> 50 years
The most serious manifestation of Graves opthalmopathy (H20 C377 P2704)
Compression of the optic nerve
Thyroid dermopathy is almost always occurs in the presence of: (H20 C377 P2704)
Moderate to severe ophthalmopathy
Thyroid acropachy is strongly associated with this clinical manifestation (H20 C377 P2704)
Thyroid dermopathy
Imaging test that may distinguish between hyper- thyroidism and destructive thyroiditis. (H20 C377 P2705)
Color-flow Doppler ultrasonography
Half-life of methimazole (H20 C377 P2706)
6 h
Half-life of propylthiouracil (H20 C377 P2706)
90 min
Usual initial dose of methimazole or carbimazole in Graves disease (H20 C377 P2706)
10-20 mg q 8-12 h
Usual initial dose of PTU in Graves disease (H20 C377 P2706)
100-200 mg q 6-8 h
TFTs and clinical manifestations are reviewed how long after initiation of thionamides? (H20 C377 P2706)
4-6 weeks
Maximum remission rates of medically treated Graves disease is achieved by how many months? (H20 C377 P2706)
12-18 months
Carbimazole or methimazole must be stopped how many days before RAI? When can it be restarted? (H20 C377 P2706)
2-3 days before, 3-7 days after
Hyperthyroidism can persist for how long before RAI takes full effect? (H20 C377 P2706)
2-3 months
Drug that is given prior to total or near total thyroidectomy for Graves disease to avoid thyrotoxic crisis and to reduce vascularity of the gland (H20 C377 P2707)
SSKI
PTU should be used in pregnant women until how many weeks gestation? (H20 C377 P2707)
14-16 weeks
High levels of maternal TSI at how many weeks gestation are associated with fetal or neonatal thyrotoxicosis (H20 C377 P2707)
26 weeks
Some authorities advocate supplementation with this drug to reduce Graves ophthalmopathy (H20 C377 P2707)
Selenium 100 mcg BID
Most common cause of acute thyroiditis in children and young adults (H20 C377 P2708)
Presence of a pyriform sinus
Diagnostic test that may be useful in distinguishing unilateral involvement of subacute thyroiditis from bleeding into a cyst or neoplasm (H20 C377 P2709)
FNA biopsy
Subacute thyroiditis evolve through three phases over this duration (H20 C377 P2708)
6 months
Silent thyroiditis is associated with the presence of TPO antibodies antepartum, and it is three times more common in women with: (H20 C377 P2709)
Type 1 diabetes mellitus
The most common clinically apparent cause of chronic thyroiditis (H20 C377 P2709)
Hashimoto thyroiditis
Aside from surgery, this treatment may be beneficial in Riedel thyroiditis (H20 C377 P2709)
Tamoxifen
Most common hormone pattern in sick euthyroid syndrome (H20 C377 P2709)
Low T3 syndrome
Iodine content of amiodarone by weight (H20 C377 P2710)
39%
High iodine levels persist for how long after discontinuation of amiodarone (H20 C377 P2710)
> 6 months
Type of amiodarone-induced thyrotoxicosis in patients with underlying thyroid abnormalities (H20 C377 P2710)
Type 1 AIT
Diagnostic test that can distinguish between type 1 and type 2 AIT (H20 C377 P2710)
Color-flow Doppler ultrasonography
Increased vascularity in type 1, decreased vascularity in type 2 AIT
Serious adverse effect of potassium perchlorate therapy (H20 C377 P2710)
Agranulocytosis
